Addressing Challenging Infection

HomePatientsLung Disease Week at the ATS2024 ▶ Addressing Challenging Infection
Addressing Challenging Infection

Addressing Challenging Infection

Welcome Message

Welcome to Lung Disease Week at the American Thoracic Society!

Thank you for joining us at the American Thoracic Society (ATS) Lung Disease Week, a forum designed to provide education and support for the millions of individuals living with respiratory, sleep-related, and critical care conditions. We are thrilled to kick off this exciting week dedicated to addressing the most challenging infections affecting the lungs. As we delve into this critical topic, we aim to foster insightful discussions, share groundbreaking research, and collaborate on innovative solutions to combat infections that pose significant threats to respiratory health.

This week (February 11th – 12th) is focused on exploring emerging pathogens to discussing novel therapeutic approaches. Our program is designed to deepen our understanding and enhance our collective efforts in managing lung infections.

Addressing challenging infections such as pseudomonas aeruginosa, respiratory syncytial virus, tuberculosis, Staphylococcus aureus, and influenza, etc. requires a multifaceted approach, including vaccination campaigns, improved diagnostics, antimicrobial stewardship programs, access to effective treatments, and ongoing research to develop new therapies and strategies for prevention. Collaboration between healthcare professionals, researchers, policymakers, and communities is essential to mitigate the impact of lung infections and improve respiratory health globally.

Thank you for joining us in this vital endeavor. Let's embark on this journey of discovery, collaboration, and innovation as we confront the challenges of lung infections head-on during ATS Lung Disease Week ‘Addressing Challenging Infection?” and invite you to participate in future ATS Lung Disease Weeks."



Siri Vaeth, MSW
Executive Director
Cystic Fibrosis Research Institute
Chair Elect, ATS Oublic Advisory Roundtable



Michele Manion
Founder & Executive Director
PCD Foundation
Immediate Past Chair, ATS Public Advisory Roundtable




The Primary Ciliary Dyskinesia Foundation is a not-for-profit 501(c)(3) patient advocacy foundation for individuals with inherited ciliary disorders and their caregivers. As a patient-focused organization, the PCDF’s mission is to provide the leadership and resources needed to support increased research, accelerated diagnosis, improved health and, ultimately, a cure for primary ciliary dyskinesia



Cystic Fibrosis Research, Inc. (CFRI) was formed in 1975 by a group of parents whose children were not expected to survive their teen years. Our mission is to fund research, provide educational and personal support and spread awareness of cystic fibrosis (CF), a life-threatening genetic disease. Our vision is Inform, engage and empower the cystic fibrosis community to reach the highest possible quality of life, as we work towards a cure.